Acutus laying off 65% of employees to focus solely on Medtronic heart device deal

The company has decided to exit the mapping and ablation business and focus its remaining cash on the Medtronic partnership.

By Nick Paul Taylor • Nov. 10, 2023

4 takeaways from Stryker’s investor day

The company’s expected return to pre-pandemic operating margins, procedure backlogs and weight loss drugs were among the topics discussed at Wednesday’s event.

By Elise Reuter • Nov. 9, 2023

Explore the Trendline➔

Medical device industry continues to turn to AI

While the industry continues to embrace artificial intelligence, there are still questions about how the new technologies need to be regulated and if they are effective.

By MedTech Dive staff

BD’s 2024 forecast comes in ‘well below’ Wall Street’s expectations

Wall Street analysts called out BD’s disappointing 2024 EPS forecast in notes to investors, following a Thursday morning earnings call.

By Ricky Zipp • Nov. 9, 2023

NICE backs use of hybrid closed loop systems for Type 1 diabetes, if companies offer discounts

The group’s recommendation gives around 150,000 people with Type 1 diabetes living in England the chance to access the systems, according to an NHS England official.

By Nick Paul Taylor • Nov. 9, 2023

J&J’s Ottava robot arriving too late to threaten Intuitive: analysts

With J&J years from approval and hospitals committed to the da Vinci system, analysts see little threat to Intuitive for the foreseeable future.

By Nick Paul Taylor • Nov. 9, 2023

Masimo lowers outlook, citing constrained hospital budgets

The patient monitoring company is also facing a slowdown in demand for the consumer audio products it acquired in a deal last year.

By Susan Kelly • Nov. 8, 2023

Recor wins FDA approval for renal denervation system

The approval makes Recor the first company to bring the treatment to the U.S. after getting an FDA panel nod in August. 

By Elise Reuter • Nov. 8, 2023

Siemens Healthineers’ Varian rebounds; execs mum on diagnostics sale rumors

The company's diagnostics unit continued to struggle amid layoffs and reports of a potential sale.

By Nick Paul Taylor • Nov. 8, 2023

Intuitive will weather weight-loss drug pressures, could see sales boost in ‘24: William Blair

Obesity drugs are constraining Intuitive's growth today, but the robotic surgery specialist could receive a sales boost in 2024 as patients reschedule bariatric procedures.

By Nick Paul Taylor • Nov. 8, 2023

J&J targets 2024 for Ottava FDA filing

The company expects to file a submission for an investigational device exemption in the second half of 2024 that will allow it to begin clinical trials for the robotic surgery system.

By Susan Kelly • Nov. 7, 2023

Zimmer Biomet’s Ivan Tornos sets priorities for first year as CEO

Tornos, who took the helm in August, said the company will grow through internal innovation and M&A.

By Elise Reuter • Nov. 7, 2023

25 attorneys general urge FDA to act fast to mitigate risk of racial bias in pulse oximetry

The AGs want the FDA to “require manufacturers and vendors of pulse oximeters to include clear, comprehensible and evidence-based warning labels.”

By Nick Paul Taylor • Nov. 7, 2023

Siemens Healthineers to lay off 300 workers, move some manufacturing to Ireland

The moves are part of a larger restructuring plan as its diagnostics business faces economic challenges.

By Ricky Zipp • Nov. 6, 2023

J&J links radiofrequency catheter to improved quality of life in atrial fibrillation study

Scores on a quality-of-life scale improved and use of antiarrhythmic drugs fell after people underwent treatment with the device.

By Nick Paul Taylor • Nov. 6, 2023

The 6 Rs of sustainability and the Hippocratic Oath

Learn how key pillars of the Hippocratic Oath can guide sustainability for medical device OEMs.

Nov. 6, 2023

5 companies to watch as medtech earnings wind down

Zimmer Biomet, BD, Masimo, Illumina and Medtronic are all set to report financial results as the medtech earnings season draws to a close.

By Nick Paul Taylor • Nov. 6, 2023

Stryker in ‘sprint back to 2019’ as procedures grow and supply chain, staffing pressures improve

The company expects a procedure backlog to boost orthopedic surgery demand in the fourth quarter and through 2024.

By Ricky Zipp • Nov. 3, 2023

Penumbra touts benefits of vacuum thrombectomy for PE in late-breaking data

An interim analysis of Penumbra’s Indigo aspiration system met its primary safety and efficacy criteria, according to data shared at the Vascular Interventional Advances Conference.

By Elise Reuter • Nov. 3, 2023

Elective procedure interest still topping pre-COVID levels, survey finds

Google searches for 20 elective surgeries in the U.S. were at 112% of pre-COVID levels in the week ended Oct. 28, according to a report from Needham analysts.

By Susan Kelly • Nov. 3, 2023

Inari Medical to buy limb-saving device maker LimFlow for up to $415M

The deal includes $250 million in cash upfront and additional payments based on reaching commercial and reimbursement milestones.

By Susan Kelly • Nov. 3, 2023

Baxter completes biopharma solutions sale, business unit revamp

The company plans to use most of the $3.7 billion in after-tax proceeds from the biopharma solutions sale to repay debt.

By Susan Kelly • Nov. 2, 2023

CooperCompanies buys reproductive health products from Cook Medical after failed takeover

The company paid $300 million to buy certain maternal fetal medicine and gynecological surgery products. 

By Elise Reuter • Nov. 2, 2023

FDA extends pandemic-era policy allowing certain device, production changes without prior approval

Companies can make limited modifications on certain devices and manufacturing processes to address supply shortages or production limitations.

By Ricky Zipp • Nov. 2, 2023

Drilling down on obesity drugs: What medtech executives are saying

Investor concerns that interest in GLP-1s will slow demand for medical devices and procedures have shaved roughly $370 billion in value from stocks across the medtech sector, according to research by Mizuho.

By Susan Kelly • Nov. 2, 2023

White House orders HHS to start collecting reports on the safety of AI in healthcare

President Joe Biden outlined the planned program as part of an executive order on “safe, secure, and trustworthy” artificial intelligence.

By Nick Paul Taylor • Nov. 1, 2023